Larvol Delta - Aptinyx-Completes-Enrollment-in-Phase-2-Study-of-NYX458-in-Cognitive-Impairment-Associated-with-Parkinsons-Disease-and-Dementia-with-Lewy-Bodies

NYX-458 - Aptinyx

https://www.businesswire.com/news/home/20220825005244/en/Aptinyx-Completes-Enrollment-in-Phase-2-Study-of-NYX-458-in-Cognitive-Impairment-Associated-with-Parkinson%E2%80%99s-Disease-and-Dementia-with-Lewy-Bodies

Aug 25, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next